Zhou P, Goldstein S, Devadas K, Tewari D, Notkins A L
Oral Infection and Immunity Branch, National Institute of Dental Research, Bethesda, MD 20892, USA.
J Immunol. 1998 Feb 1;160(3):1489-96.
Plasmids containing single chain Fv (scFv) non-neutralizing human anti-HIV-1 gp41 Ab cDNA, with or without endoplasmic reticulum (ER) or trans-Golgi network (TGN) retention signals, were constructed. Stable transfectants expressing these scFvs then were generated from COS-7 cells and HIV-1-susceptible CD4+ human T cells (Jurkat). scFv without a retention signal was secreted from cells, whereas scFv with an ER or TGN retention signal remained primarily within targeted intracellular compartments. The expression of scFv, scFv-ER, and scFv-TGN did not adversely affect the appearance of uninfected cells, as measured by growth rate or CD4 expression. Pulse-chase experiments revealed that the t(1/2) of scFv-ER and scFv-TGN within cells was greater than 24 h and less than 9 h, respectively. The scFv-ER and scFv-TGN bound HIV gp160, and the scFv-ER-gp160 and the scFv-TGN-gp160 complexes were stable within HIV-infected transfectants. Further studies revealed that the maturation processing of gp160 into gp120 and gp41 was blocked in the scFv-ER transfectants, but not in the scFv-TGN transfectants. Moreover, HIV replication, as measured by p24, was inhibited by up to 99% in cells transfected with scFv-ER or scFv-TGN, but was not inhibited in cells transfected with the secretory form of scFv. It is concluded that the targeting of non-neutralizing anti-HIV-1 Abs to specific intracellular compartments blocks HIV replication and represents a potential therapeutic strategy for protecting uninfected lymphopoietic stem cells from HIV-1-infected patients.
构建了含有单链Fv(scFv)非中和性人抗HIV-1 gp41抗体cDNA的质粒,该质粒带有或不带有内质网(ER)或反式高尔基体网络(TGN)滞留信号。然后从COS-7细胞和对HIV-1敏感的CD4 +人T细胞(Jurkat)中产生表达这些scFv的稳定转染子。没有滞留信号的scFv从细胞中分泌出来,而带有ER或TGN滞留信号的scFv主要保留在靶向的细胞内区室中。通过生长速率或CD4表达测量,scFv、scFv-ER和scFv-TGN的表达对未感染细胞的外观没有不利影响。脉冲追踪实验表明,细胞内scFv-ER和scFv-TGN的半衰期分别大于24小时和小于9小时。scFv-ER和scFv-TGN与HIV gp160结合,并且scFv-ER-gp160和scFv-TGN-gp160复合物在HIV感染的转染子中是稳定的。进一步的研究表明,在scFv-ER转染子中,gp160成熟加工为gp120和gp41的过程被阻断,但在scFv-TGN转染子中未被阻断。此外,用scFv-ER或scFv-TGN转染的细胞中,通过p24测量的HIV复制被抑制高达99%,但在用scFv分泌形式转染的细胞中未被抑制。结论是,将非中和性抗HIV-1抗体靶向特定细胞内区室可阻断HIV复制,并代表了一种保护未感染的造血干细胞免受HIV-1感染患者感染的潜在治疗策略。